NASDAQ:ACXP

Acurx Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy ACXP

*Your capital is at risk

$1.42

-0.0900 (-5.96%)

At Close: Jun 23, 2026

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

08:00am, Thursday, 01'st Jul 2021

STATEN ISLAND, N.Y. , July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

04:01pm, Tuesday, 29'th Jun 2021

STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diff

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by